GlassScriptPhysician profile
Shenika N Magee
NPI 1639761547
$13,399.83
in general payments reported to CMS, 2019-2025
27 companies · $4,791 in 2025
The $4,791 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $537 · 2022: $2,379 · 2023: $2,389 · 2024: $3,305 · 2025: $4,791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $2.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,482.37 |
| Education | $2.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,764.01 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $1,282.44 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $1,278.98 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,179.43 | 2021-2025 | Fanapt, Hetlioz |
| Abbvie INC. | $988.61 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $980.28 | 2021-2025 | Caplyta |
| Bausch Health US, LLC | $879.50 | 2021-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $830.18 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $748.38 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Axsome Therapeutics, INC. | $673.23 | 2022-2025 | Auvelity, Sunosi |
| Corium, LLC | $628.55 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $487.53 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $387.25 | 2021-2024 | Trintellix |
| Tris Pharma INC | $230.21 | 2023-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $185.34 | 2024-2025 | Cobenfy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $148.65 | 2023-2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $129.39 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $118.87 | 2023-2025 | Qelbree, Qelbree |
| Gilead Sciences, INC. | $116.99 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $99.75 | 2025 | |
| Collegium Pharmaceutical, INC. | $62.32 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $61.92 | 2023-2024 | Quviviq |
| Neos Therapeutics, LP | $40.71 | 2022 | |
| Noven Therapeutics, LLC | $32.24 | 2024 | Secuado, Xelstrym |
| Eisai INC. | $30.73 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $18.26 | 2024 | Daybue |
| Tonix Medicines, INC. | $16.08 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shenika Magee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.